Taconic and Cellaria have a shared goal to create relevant tools for cancer,â€ť said David Deems, chief executive officer
Online PR News – 16-May-2015 – 176 Benner Road Royersford 19468 United States – AGREE TO SCIENTIFIC COLLABORATION TO FACILITATE XENOGRAFT USE IN ONCOLOGY RESEARCH
Novel Technology Will Improve Process of Generating Cells from Patient-Derived Tumors
HUDSON, NY â€“ March 25, 2015 - Taconic Biosciences and Cellaria Biosciences announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellariaâ€™s novel methodologies for generating cells from patient tumors will complement Taconicâ€™s industry-leading portfolio of tissue humanized mouse models, which are well-suited as hosts for PDXs.
The value of using patient-derived tumors in oncology and immuno-oncology research has been well documented, but traditional methods of obtaining tumor cell material have proven labor-intensive and expensive, inhibiting researchersâ€™ access to this material. Cellariaâ€™s innovative approach to propagating tumor cell material and generating PDX banks significantly reduces the associated labor and costs, making patient-derived tumor models more accessible to investigators.
â€śOur scientific collaboration with Cellaria is a prime example of Taconic continually pushing the boundaries of technology to improve the utility of humanized animal models in biomedical research,â€ť said Todd Little, president of Corporate Development, Taconic Biosciences. â€śBy collaborating with a company that has achieved great success in generating cell lines from patient-derived tumors, Taconic will be able to deliver more predictive tissue humanized models that will improve and accelerate oncology research and drug discovery.â€ť
Cellariaâ€™s advanced technology facilitates the creation of PDX banks in a more controlled manner, supports more effective tumor engraftments on study animals, and enables harvesting sufficient tumor material for use in long-term and repeat studies. The companiesâ€™ initial collaborations will focus on the creation of breast cancer cell lines from PDX models for which Taconic holds licenses from the University of Utah.
â€śTaconic and Cellaria have a shared goal to create relevant tools for cancer,â€ť said David Deems, chief executive officer, Cellaria. The new models created through this collaboration have enormous potential to better define target patient populations and evaluate the efficacy of new therapies.â€ť
About Taconic Biosciences, Inc.
Taconic Biosciences is a global provider of genetically engineered rodent models and services. Founded in 1952, Taconic helps the biotechnology and pharmaceutical communities acquire, custom generate, breed, precondition, test, and distribute highly relevant research models worldwide. Specialists in Rodent Humanization and GEMS Management, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe and maintains distributor relationships in Asia.
About Cellaria Biosciences
Cellaria Biosciences offers pre-clinical models to better represent tumor-host interactions and accelerate oncology drug discovery and development. This technology greatly simplifies the creation of cell lines and improves the representation of tumors in target patient populations to better capture their genetic and epigenetic diversity. In addition to the Cellaria Cell Line Bank and Renaissance Essential Tumor Media (RETM), the company provides expert services for the derivation of high quality, well characterized custom cell lines from sourced tissue and develops custom assays using our 3D and in vivo models for drug discovery and development. For more information, visit www.cellariabio.com.